Daily Financial Update
Your Morning Jolt: FDA Shake-Up, Earnings Beats & Geopolitical Flashpoints
Market Pulse: Biotech approvals and industrial strength edged markets into a cautiously optimistic mood yesterday, with sector rotations grabbing headlines before the bell.
Key Movers: Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD and Thermo Fisher Scientific Stock Surges 8.71% After Strong Q2 Earnings Beat and Raised Full-Year Guidance steered the rally, while American Express Sinks 6% After Q2 Earnings Beat as Visa, Mastercard Hold Steady kept credit names in focus.
Macro & Politics: Analysts Map 4 Potential USA-Iran Conflict Scenarios highlights Gulf flashpoints, and Washington vs. Beijing: AI Gets Political warns of U.S. scrutiny on Chinese models, layering risk premiums across commodities and tech.
What’s Next: Watch for July jobs data and any fresh Fed commentary ahead of the open.
Market Commentary
What everyone’s missing is how the FDA nod for LYTENAVA™ (Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD, GlobeNewswire) isn’t just a win for retina care – it’s a shot across big pharma’s bow that could spark a M&A feeding frenzy. As chatter heats up, any doubt on this catalyst could trigger a classic retail short squeeze in names with weak float, so don’t sleep on regulatory catalysts.
Combine Thermo Fisher Scientific Stock Surges 8.71% After Strong Q2 Earnings Beat and Raised Full-Year Guidance (Ibtimes.com.au) with the detailed flashpoints in Analysts Map 4 Potential USA-Iran Conflict Scenarios (Rigzone) and you get a thesis: as government labs hike R&D spend, energy volatility looms if the Strait of Hormuz flares. That cross-asset correlation is a golden thread nobody’s highlighting.
Action time: load up on pricing-power names and ophthalmic innovators while skewing some exposure to energy volatility trades. If you’re positioned for regulatory winners and hedged against a supply shock, you’ll be playing both sides of this deck to perfection.
📈 Breaking Financial News
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation
Intel Stock Falls 4.18% Friday Despite Strong Earnings Beat, as July's Sharp Rally Continues to Cool
Intel's shares fell despite a strong earnings report and increased capital spending plans, as investors took profits following a significant rally. The company's AI-driven growth and future outlook remain positive.
American Express Sinks 6% After Q2 Earnings Beat as Visa, Mastercard Hold Steady
American Express just posted a clear earnings beat, yet its stock is cratering while Visa and Mastercard barely flinch. The divergence points to a specific t…
Thermo Fisher Scientific Stock Surges 8.71% After Strong Q2 Earnings Beat and Raised Full-Year Guidance
Thermo Fisher Scientific's shares surged after reporting strong Q2 results, surpassing expectations and raising full-year guidance, indicating a recovery in the life sciences sector.
Verizon Earnings Beat, Revenue Light Amid Lower Phone Upgrades
Verizon topped Q2 earnings estimates and added more “postpaid” phone subscribers than expected. But revenue fell short.
The post Verizon Earnings Beat, Revenue Light Amid Lower Phone Upgrades appeared first on Investor's Business Daily.
Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
🔍 Market Analysis & Insights
Intel Stock Jumps On Chipmaker's Big Q2 Earnings Beat – Investor's Business Daily
Intel Stock Jumps On Chipmaker's Big Q2 Earnings BeatInvestor's Business Daily Intel's stock jumps as chipmaker rides AI boom to fastest revenue growth in almost 15 yearsCNBC Intel Benefits From a New Shift in A.I. SpendingThe New York Times Intel earnings gi…
IMAX Corp (IMAX) Rockets 11.86% on Earnings Beat, H2 Optimism
Entertainment technology firm IMAX Corp. (NYSE:IMAX) rallied for a second day on Thursday, nearly hitting its 52-week high, after reporting a solid earnings…
SAP shrugs off AI eating software fears with big earnings beat
Enterprise software giant SAP SE’s stock inched up in late trading today after it shook off concerns that its business might become a victim of the artificial intelligence boom by posting solid results in its latest earnings report. The strong numbers posted …
AMD Has an Agentic AI Advantage Over Nvidia That Keeps Me Buying Again and Again
Agentic AI rewires what an AI server actually needs, and most investors are still thinking about this race the wrong way. The company that quietly controls t…
AMD takes on Nvidia, US takes on Chinese AI models and AI spending still spooks investors
Maybe Nvidia ultimately won’t win the entire AI enchilada, even as it reminded everyone this week that it offers everything you need to build AI factories. This week, Advanced Micro Devices also announced a raft of new graphics processing units, central proce…
quietly engineered by Elon Musk… could end that crisis forever. And one tiny company is sitting at the center of it all. Musk is expected to make an announcement any day now. See more about this secret project here.
💰 Investment Opportunities
Here Are 3 AI Companies Betting They Can Replace Doctors
Three AI startups—Doctronic, Certuma and Ada Health—are racing to replace physicians. A physician describes their approach, Here's the data, funding and regulatory hurdles.
Analysts Map 4 Potential USA-Iran Conflict Scenarios
Rystad Energy mapped four potential U.S.-Iran conflict scenarios to assess their impact on oil prices.
The White House’s MAHA Gatekeeper
A policy wonk who could lead the FDA has angered “Make America Healthy Again” activists.
From near-collapse to $689 billion: Inside Larry Culp’s turnaround of GE
Also: All the news and watercooler chat from Fortune.
Mukesh Ambani’s long game: How Reliance could turn a 3-year spending spree into Rs 90,000 crore of free cash flow
Reliance Industries could generate nearly Rs 90,000 crore in cumulative free cash flow over FY26-FY28 as its heavy investment cycle eases, brokerages say. Stronger earnings from energy and Jio, coupled with moderating capex, may reduce leverage and mark the b…
quietly engineered by Elon Musk… could end that crisis forever. And one tiny company is sitting at the center of it all. Musk is expected to make an announcement any day now. See more about this secret project here.